All Neurosciences articles – Page 6
-
ArticleAdvanced drug development for neurodegenerative diseases with α-synuclein
Discover how α-synuclein tests are transforming the diagnosis and treatment of neurodegenerative diseases, offering hope for earlier detection, better-targeted therapies and faster drug development.
-
NewsStudy aims to stop Alzheimer’s with stem cell infusions
Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer's disease before symptoms emerge, an approach that could revolutionise treatment strategies, offering new hope for at-risk individuals.
-
News
Alzheimer’s treatment targets root causes, not just symptoms
Porosome Therapeutics has made a groundbreaking discovery in Alzheimer’s research by targeting the disease’s molecular causes, focusing on restoring secretory and metabolic functions. This approach could not only slow progression but potentially reverse early-stage pathology.
-
NewsDrug OLX-07010 shows promise in treating tau diseases
OLX-07010, a new drug from Oligomerix, shows potential in reducing tau protein tangles, a key factor in Alzheimer's and other tau-related diseases. Early studies suggest it could be a breakthrough in targeting tau aggregation and improving brain function.
-
ArticleThe future of mental health treatment: Zelquistinel's role
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
-
NewsRett syndrome discovery could lead to better treatments
Researchers have identified early molecular changes in Rett syndrome that could lead to improved treatments for the condition.
-
NewsNew genetic mechanism could lead to RNA therapies for mental health
Researchers at the Medical University of South Carolina have discovered a key genetic mechanism that could lead to RNA-based therapies for psychiatric disorders triggered by emotional experiences.
-
NewsNovartis licenses innovative treatment for Huntington’s disease
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
-
NewsBlood-brain barrier breakthrough for ALS and Alzheimer's disease
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
-
NewsPreventing F-actin build-up improves drosophila healthspan
Disrupting F-actin in aged brains restored brain autophagy to youthful levels and reversed some cellular markers of brain ageing.
-
ReportBeyond the lab: antibodies
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
-
NewsSpecific HERV expression signatures linked to MS and ALS
The study identified which specific HERVs are important in increasing susceptibility for neurodegenerative diseases.
-
NewsMechanism that controls reactivation of neural stem cells discovered
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
-
NewsPromising development of new drug to treat Alzheimer’s disease
In lab and fruit fly studies, the new peptide inhibitor effectively acted on both major aggregation-promoting hotspots of Tau proteins.
-
NewsNew link found between immune system and neurological disease
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
-
NewsNew humanised neuroinflammation in vitro platform
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
-
ArticleDrug candidates with blockbuster potential for CNS diseases
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
-
ArticleA novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates ...
-
NewsBrain organoids: investigating the progression of Huntington’s disease
Researchers found that HD can impair early brain development through defects associated with mitochondrial dysfunction.
-
ArticleWomen in STEM with Kristina Torfgard
Introducing Kristina Torfgard! Holding a PhD in Clinical Pharmacology, she has over 30 years’ experience in drug development and is currently CEO of IRLAB Therapeutics.